retatrutide type 2 diabetes phase 2 results 2024 Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, 3 Retatrutide: A Promising Breakthrough for

Clinical and patient-reported outcomes from patients with nonalcoholic fatty liver disease across the world: data from the global non-alcoholic steatohepatitis (NASH)/non-alcoholic fatty liver disease (NAFLD) registry

If you're using or considering any prescription weight-loss medication, mention any patches you're using too

Using rodent models of obesity and metabolic dysfunction, the research group demonstrated that the triple-agonist approach produced meaningful reductions in body weight and improved glycaemic parameters compared to both placebo and comparator compounds targeting fewer receptors

If you qualify for either medication and can afford it, doctors say theyre worth considering

These include Alzheimers disease, Parkinsons disease and alcohol use disorder (Figure 2)